CQS Cayman LP: LBRDA position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of CQS Cayman LP on LBRDA, newest first. How the timeline and the estimate are built.
CQS Cayman LP held 44,093 LBRDA shares at 2019-09-30 per its 13F-HR filed 2019-11-12.
the latest 13F is the newest step
- period ended2019-09-3013F 44,093 sharesChange vs previous 13F +44,093 shares
0.22% of the 13F portfolio, value $4,608,000.
13F-HR 0001085146-19-002850 filed by CQS Cayman LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2018-12-3113F 0 sharesChange vs previous 13F -26,246 shares
13F-HR 0001085146-19-000651 filed by CQS Cayman LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2018-09-3013F 26,246 sharesChange vs previous 13F -19,108 shares
0.14% of the 13F portfolio, value $2,213,000.
13F-HR 0001085146-18-002536 filed by CQS Cayman LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2018-06-3013F 45,354 sharesChange vs previous 13F 0 shares
0.24% of the 13F portfolio, value $3,430,000.
13F-HR 0001085146-18-002015 filed by CQS Cayman LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2018-03-3113F 45,354 sharesChange vs previous 13F -113,707 shares
0.23% of the 13F portfolio, value $3,846,000.
13F-HR 0001085146-18-001310 filed by CQS Cayman LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2017-12-3113F 159,061 sharesChange vs previous 13F not available
0.87% of the 13F portfolio, value $13,528,000.
13F-HR 0001085146-18-000502 filed by CQS Cayman LP
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).